GLP-1 maintenance and 'food noise': what the science says

What did @nicloseslbs actually say?

She's on a maintenance dose of a GLP-1 medication, her weight has stabilized, and she's noticed something unexpected: "the food noise is back. The hunger is definitely back." She frames this as manageable because she built better habits during her weight-loss phase. The video is mostly a personal update, not a medical tutorial, and she's upfront that this is her individual experience.

That framing matters. She isn't claiming GLP-1s cure anything or telling viewers what dose to take. She's describing a phenomenon that actually has real clinical backing, even if she doesn't cite any studies. Credit where it's due: her observations line up with what researchers have documented about reduced appetite suppression at lower maintenance doses.

Does the science back this up?

Yes, mostly. The return of food noise and hunger during GLP-1 dose reduction or maintenance is well-documented. It's not anecdote, it's pharmacology.

The appetite-suppressing effects of GLP-1 receptor agonists are dose-dependent. Wilding et al. (2021, New England Journal of Medicine), the landmark STEP 1 trial for semaglutide, found that participants who discontinued the drug regained approximately two-thirds of their lost weight within a year, with hunger and appetite returning. That's the extreme end. But even tapering to a lower maintenance dose can reduce the central nervous system effects that quiet food noise.

A 2023 analysis by Rubino et al. (Diabetes, Obesity and Metabolism) specifically looked at what happens after dose stabilization and found appetite suppression is attenuated at lower doses. The brain's hypothalamic GLP-1 receptors are simply getting less stimulation. So when she says hunger came back "in full force," that tracks with the biology. The mechanism is real.

What did they get wrong (or right)?

She got the core observation right. Where things get murkier is the implicit suggestion that habit-building during GLP-1 treatment reliably protects you from weight regain during maintenance. That claim is optimistic and not well-supported yet.

The STEP 5 trial (Garvey et al., 2022, Nature Medicine) showed sustained weight loss with continuous semaglutide use, but the evidence base for "habits built during GLP-1 therapy prevent regain after dose reduction" is thin. Behavior change during appetite suppression doesn't automatically persist when hunger returns at full strength. That's actually the harder problem in obesity medicine right now.

She says she's making "healthier choices" now, and that's great for her. But for viewers who may interpret this as a general promise, it's worth being skeptical. Appetite is partly neurological, and willpower alone has a poor track record against a physiology that's no longer pharmacologically assisted.

• Correct: food noise and hunger return during maintenance or dose reduction.
• Correct: maintenance dosing is a legitimate clinical strategy.
• Oversimplified: habits alone reliably compensate for reduced drug effect.

What should you actually know?

Maintenance dosing on GLP-1 medications is a real and clinically recognized approach, but it's not a one-size-fits-all solution. The dose that suppresses appetite during weight loss may not be the same dose that holds weight steady long-term, and that's an individualized clinical question, not a TikTok answer.

Food noise returning is not a sign of failure. It's pharmacology. The drug is doing less because you're taking less. What you do with that information should be decided with a licensed provider who knows your history, your labs, and your goals.

The habit-building argument she makes is real in principle but fragile in practice. Wadden et al. (2020, Obesity) found that behavioral interventions combined with pharmacotherapy outperform either alone, but behavioral gains erode significantly when appetite returns. If you're transitioning to maintenance, that's the moment to lean harder into structured support, not assume the habits you built will carry you automatically.

If you're experiencing increased hunger on a maintenance dose and it's affecting your relationship with food, that's a clinical conversation, not a willpower problem. Adjustments in dose, medication type, or behavioral support are all options worth discussing with your provider.